Growth hormone (GH) insensitivity syndrome (GHIS) is a rare clinical condition in which production of insulin-like growth factor 1 is blunted and, consequently, postnatal growth impaired. Autosomal-recessive mutations in signal transducer and activator of transcription (STAT5B), the key signal transducer for GH, cause severe GHIS with additional characteristics of immune and, often fatal, pulmonary complications. Here we report dominant-negative, inactivating STAT5B germline mutations in patients with growth failure, eczema, and elevated IgE but without severe immune and pulmonary problems. These STAT5B missense mutants are robustly tyrosine phosphorylated upon stimulation, but are unable to nuclear localize, or fail to bind canonical STAT5B DNA response elements. Importantly, each variant retains the ability to dimerize with wild-type STAT5B, disrupting the normal transcriptional functions of wild-type STAT5B. We conclude that these STAT5B variants exert dominant-negative effects through distinct pathomechanisms, manifesting in milder clinical GHIS with general sparing of the immune system.

Klammt, J., Neumann, D., Gevers, E. F., Andrew, S. F., Schwartz, I. D., Rockstroh, D., Colombo, R., Sanchez, M. A., Vokurkova, D., Kowalczyk, J., Metherell, L. A., Rosenfeld, R. G., Pfaffle, R., Dattani, M. T., Dauber, A., Hwa, V., Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation, <<NATURE COMMUNICATIONS>>, 2018; 9 (1): 2105-N/A. [doi:10.1038/s41467-018-04521-0] [http://hdl.handle.net/10807/170469]

Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation

Colombo, Roberto;
2018

Abstract

Growth hormone (GH) insensitivity syndrome (GHIS) is a rare clinical condition in which production of insulin-like growth factor 1 is blunted and, consequently, postnatal growth impaired. Autosomal-recessive mutations in signal transducer and activator of transcription (STAT5B), the key signal transducer for GH, cause severe GHIS with additional characteristics of immune and, often fatal, pulmonary complications. Here we report dominant-negative, inactivating STAT5B germline mutations in patients with growth failure, eczema, and elevated IgE but without severe immune and pulmonary problems. These STAT5B missense mutants are robustly tyrosine phosphorylated upon stimulation, but are unable to nuclear localize, or fail to bind canonical STAT5B DNA response elements. Importantly, each variant retains the ability to dimerize with wild-type STAT5B, disrupting the normal transcriptional functions of wild-type STAT5B. We conclude that these STAT5B variants exert dominant-negative effects through distinct pathomechanisms, manifesting in milder clinical GHIS with general sparing of the immune system.
2018
Inglese
Klammt, J., Neumann, D., Gevers, E. F., Andrew, S. F., Schwartz, I. D., Rockstroh, D., Colombo, R., Sanchez, M. A., Vokurkova, D., Kowalczyk, J., Metherell, L. A., Rosenfeld, R. G., Pfaffle, R., Dattani, M. T., Dauber, A., Hwa, V., Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation, <<NATURE COMMUNICATIONS>>, 2018; 9 (1): 2105-N/A. [doi:10.1038/s41467-018-04521-0] [http://hdl.handle.net/10807/170469]
File in questo prodotto:
File Dimensione Formato  
170469OA.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.74 MB
Formato Adobe PDF
1.74 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/170469
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 87
social impact